Martin S. Maron, MD

Expert cardiologists share strategies for educating patients on the treatment and management of hypertrophic cardiomyopathy.

Drs Steve R. Ommen, Martin S. Maron, Javed Butler, and James Januzzi provide insight on the evolving treatment landscape for obstructive hypertrophic cardiomyopathy.

A panel of experts in cardiovascular medicine review the use of mavacamten as seen in the VALOR-HCM study for patients with symptomatic oHCM who are eligible for septal reduction therapy.

Martin S. Maron, MD, examines long-term data with mavacamten for oHCM treatment that was presented at ACC 2022.

Cardiac specialists discuss improvement in health status with different treatments for hypertrophic cardiomyopathy.

John A. Spertus, MD, MPH, and Martin S. Maron, MD comment on the role of mavacamten in oHCM as seen in the EXPLORER-HCM trial.

Steve R. Ommen, MD, discusses the use of novel agents in the pipeline for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

Steve R. Ommen, MD, leads a discussion on factors to consider when choosing treatment for hypertrophic cardiomyopathy (HCM).

Experts in cardiology review invasive treatments, challenges with HCM treatments, and how to optimize treatment for patients.

Drs Javed Butler, Martin S. Maron, Steve R. Ommen, and James Januzzi provide insight on approaching treatment of HCM with pharmacologic and nonpharmacologic interventions.

Steve R. Ommen, MD; and Martin S. Maron, MD, review the role of AHA/ACC guidelines, imaging techniques, and circulating biomarkers in approaching the diagnosis and treatment of hypertrophic cardiomyopathy.

John A. Spertus, MD, MPH, comments on the effect of oHCM on health status and quality of life for patients.

Drs Steve R. Ommen, Martin S. Maron, John A. Spertus, Javed Butler, and James Januzzi provide insight on the presentation of nonobstructive and obstructive hypertrophic cardiomyopathy.

Steve R. Ommen, MD, leads a review of common mutations seen in hypertrophic cardiomyopathy and the role of biomarkers and genetic testing in HCM.

Martin S. Maron, MD, discusses the incidence and prevalence of hypertrophic cardiomyopathy and age of disease expression.